AVIR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
35.1M
-26.9%
48.0M
-12.6%
54.9M
+20.6%
45.6M
+10.2%
41.3M
R&D
28.1M
-31.6%
41.1M
-14.0%
47.8M
+24.7%
38.3M
+18.8%
32.3M
SG&A
6.9M
+1.1%
6.9M
-3.4%
7.1M
-1.4%
7.2M
-20.4%
9.1M
Operating Income
-35099000
+26.9%
-48008000
+12.6%
-54934000
-20.6%
-45567000
-10.2%
-41345000
EBITDA
-34995000
+26.9%
-47904000
+12.6%
-54830000
-20.6%
-45463000
-10.2%
-41241000
Net Income
-32933000
+27.5%
-45440000
-1.3%
-44867000
-6.7%
-42049000
-13.2%
-37161000
EPS (Basic)
$-0.41
+28.1%
$-0.57
+1.7%
$-0.58
-9.4%
$-0.53
-20.5%
$-0.44
EPS (Diluted)
$-0.41
+28.1%
$-0.57
+1.7%
$-0.58
-9.4%
$-0.53
-20.5%
$-0.44
Shares (Diluted)
80.1M
+1.1%
79.2M
+1.5%
78.0M
-1.3%
79.1M
-5.6%
83.7M
Atea Pharmaceuticals (AVIR) โ€” Financials